A vial label stating 99% purity is a claim. The paperwork behind that claim is the evidence. For buyers asking which documents verify peptide quality, the starting point is a batch-specific Certificate of Analysis, supported by analytical data that can be matched to the exact material supplied.
For research compounds, quality verification should answer a few clear questions: what is in the vial, how pure is it, how was that result measured, and does the report relate to the same batch you are buying? A professional supplier should make those answers easy to assess without relying on broad marketing statements.
The core document: a batch-specific Certificate of Analysis
A Certificate of Analysis, usually called a COA, is the primary quality document for a peptide. It records the results of defined analytical tests for a particular batch. This point matters. A generic certificate for a product name is not equivalent to a report tied to a specific production lot.
Start by checking the product identity, peptide name, batch or lot number, date of analysis and reporting laboratory details. The lot number on the COA should correspond with the batch identifier supplied with the material. If there is no batch reference, there is no reliable way to connect the stated result to the vial in front of you.
A useful COA also identifies the testing method and gives a clear result rather than an unsupported pass statement. For many research peptides, the headline purity result will be generated by HPLC or UHPLC analysis. Mass spectrometry is commonly used alongside it to confirm molecular identity.
The document should also state the reported purity as a percentage. A 99%+ purity specification is meaningful only when the method, result and batch relationship are visible. It does not mean every possible quality attribute has been tested, nor does it remove the need to examine the rest of the record.
How HPLC data verifies peptide purity
High-performance liquid chromatography, or HPLC, separates components in a sample. Its value is simple: it shows whether the target peptide is the dominant component and whether other detectable peaks are present.
A COA may state an HPLC purity result, but the supporting chromatogram provides more context. The principal peak should be clearly identifiable, and the stated area percentage should align with the purity figure on the certificate. Small secondary peaks may be present even in high-purity material. What matters is that they are not concealed and that the overall result meets the supplier's stated specification.
There are limits to what a chromatogram can prove. HPLC purity is generally based on UV response and does not automatically identify every impurity. Different substances can also respond differently at a chosen wavelength. This is why HPLC should be read as one part of a wider analytical record, rather than as a standalone promise.
For products such as BPC-157, GHK-Cu or MOTS-C supplied for research use, the analytical method should be appropriate to the compound being assessed. A supplier should be able to explain what its result represents without overstating it.
What to look for on an HPLC report
Check that the report names the analyte, includes a sample or batch reference, identifies the method or instrument conditions, and records a numerical purity result. A chromatogram image with no sample details has limited evidential value. Equally, a purity percentage with no stated method leaves an unnecessary gap.
The appearance of the trace alone is not enough for most buyers to make a scientific judgement. Use it to confirm consistency between the raw data and the COA, not as a substitute for batch traceability.
Mass spectrometry confirms molecular identity
Where HPLC assesses chromatographic purity, mass spectrometry helps confirm that the principal component has the expected molecular mass. For peptide verification, this is a critical second line of evidence.
A mass spectrum should show an observed mass that is consistent with the expected mass for the named peptide. Depending on the instrument and reporting format, the document may show multiple charge states, a deconvoluted mass, or both. The exact presentation can vary, but the report should still make the identity conclusion clear.
Mass confirmation and purity are related but different. A sample can show the expected mass while still containing impurities. It can also have a strong HPLC purity result without sufficient proof that the main peak is the intended peptide. Reviewing both HPLC and MS data reduces that uncertainty.
For copper-containing compounds such as GHK-Cu, the expected mass and spectral pattern may differ from an uncomplexed peptide. That is not automatically a concern. It does, however, make method-specific documentation more valuable than generic paperwork copied between products.
Additional documents that strengthen confidence
The required level of documentation depends on the compound, the intended research application and the buyer's own controls. A COA, HPLC result and mass spectrum are usually the central evidence for identity and stated purity. Additional records can provide useful assurance where the work demands more detail.
A credible quality file may also include the following:
- Residual solvent analysis, commonly performed by gas chromatography, where solvent carryover is relevant to the synthesis process.
- Water content or moisture testing, which can be useful for hygroscopic or lyophilised materials and for interpreting net content.
- Peptide content or assay data, particularly where counterions, salts or water content affect the difference between total material mass and actual peptide content.
- Microbiological or endotoxin results, where these tests are relevant to the stated research specification. They should never be assumed merely because a product is described as high purity.
- Stability, storage and handling records, which help establish the conditions under which the material should be retained before use in a research setting.
Traceability is what turns a report into proof
A technically sound test result has less value if it cannot be linked to the item shipped. Batch traceability is therefore central to peptide quality control.
The product label, outer packaging and COA should use compatible identifiers. Look for a lot number, batch number or another unique code. The certificate should also carry an issue date, and ideally a responsible signatory or laboratory approval. A document without identifying details may look polished while offering little practical accountability.
It is also worth separating a supplier's internal testing record from independent third-party analysis. Either can be informative, provided the source and scope are transparent. Third-party testing may offer additional separation from the manufacturing process, but it is not automatically superior if the report is old, incomplete or unrelated to the current lot. Conversely, an internal COA can be useful when it is batch-specific, method-led and supported by readable raw data.
The strongest position is clear disclosure: who performed the testing, what was tested, when it was tested, and which lot the results apply to.
Common paperwork gaps to treat cautiously
Some warning signs are straightforward. A certificate that has no batch number, no test date, no method and no laboratory information cannot verify much beyond a supplier's assertion. The same applies to a single COA repeatedly presented for multiple batches.
Be cautious with certificates that only say “passes” or “complies” without results. A proper analytical document should provide a measurable outcome, such as an HPLC area percentage or observed mass, alongside the acceptance criteria where relevant.
Poor document quality is not always proof that the material fails specification. Records can be formatted differently between laboratories, and some suppliers limit the raw data they publish. However, quality claims become harder to evaluate when supporting information is vague, undated or impossible to associate with the supplied lot.
A practical document check before ordering
Before selecting a research peptide supplier, ask whether the product has a batch-specific COA, whether HPLC purity and mass spectrometry identity data are available, and whether the lot on the paperwork can be matched to the product received. Those three checks address the most common sources of uncertainty.
Then assess the claim in context. A high stated purity is useful, but the best indicator of dependable sourcing is a consistent evidence trail: a named compound, a defined batch, appropriate testing and results presented clearly. Biochemi's quality-led approach is built around that standard of transparent, batch-level assurance.
Good peptide documentation does not need to be complicated. It needs to be specific enough that a careful buyer can follow the evidence from the analytical result to the exact research material supplied.